Golimumab pharmacokinetics in ulcerative colitis: a literature review

about

Tumor necrosis factor alpha in sleep regulation.

P2860

Q47662147-E5A32398-4725-496A-B750-C24A6AEE6F5A

P2860

Golimumab pharmacokinetics in ulcerative colitis: a literature review

Item

http://www.wikidata.org/entity/Q37671983

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Golimumab pharmacokinetics in ulcerative colitis: a literature review

@en

Golimumab pharmacokinetics in ulcerative colitis: a literature review.

@nl

type

Item

label

Golimumab pharmacokinetics in ulcerative colitis: a literature review

@en

Golimumab pharmacokinetics in ulcerative colitis: a literature review.

@nl

prefLabel

Golimumab pharmacokinetics in ulcerative colitis: a literature review

@en

Golimumab pharmacokinetics in ulcerative colitis: a literature review.

@nl

P1476

Golimumab pharmacokinetics in ulcerative colitis: a literature review

@en

P2093

Ines Harzallah

http://www.w3.org/2001/XMLSchema#string

Josselin Rigaill

http://www.w3.org/2001/XMLSchema#string

Nicolas Williet

http://www.w3.org/2001/XMLSchema#string

P2860

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis

Golimumab for the treatment of ulcerative colitis

Immunogenicity to biologics: mechanisms, prediction and reduction.

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Immunoglobulin G4: an odd antibody.

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.

Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.

P304

89-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1756283X16676194

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stéphane Paul

X Roblin

P577

2016-11-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28286562

http://www.w3.org/2001/XMLSchema#string

P932

5330616

http://www.w3.org/2001/XMLSchema#string

Golimumab pharmacokinetics in ulcerative colitis: a literature review

about

P2860

P2860

Golimumab pharmacokinetics in ulcerative colitis: a literature review

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932